Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Fanconi anemia complementation group D1”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableTemporarily pausedNCT02993068
What this trial is testing

Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)

Who this might be right for
BARD1 Gene MutationBRCA1 Gene MutationBRCA2 Gene Mutation+12 more
M.D. Anderson Cancer Center 5,200
Early research (Phase 1)Study completedNCT03586661
What this trial is testing

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Deleterious BRCA1 Gene MutationDeleterious BRCA2 Gene MutationEndometrial Adenocarcinoma+8 more
M.D. Anderson Cancer Center 31
Testing effectiveness (Phase 2)Study completedNCT02282345
What this trial is testing

Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer

Who this might be right for
Breast AdenocarcinomaDeleterious BRCA1 Gene MutationDeleterious BRCA2 Gene Mutation+2 more
M.D. Anderson Cancer Center 36
Testing effectiveness (Phase 2)Looking for participantsNCT05485766
What this trial is testing

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast NeoplasmsTriple Negative Breast CancerBreast Neoplasms+5 more
Okayama University 23
Not applicableUnknownNCT02474264
What this trial is testing

The Link Between BRCA Mutation and Endothelial Function

Who this might be right for
BRCA1 Gene MutationBRCA2 Gene Mutation
Rabin Medical Center 82
Not applicableActive Not RecruitingNCT02530008
What this trial is testing

Breast Cancer 2-PREVENT Translational Center of Excellence (TCE) - Metastatic Markers of Recurrent Tumor Phenotype for Breast Cancer

Who this might be right for
Women With Suspected or Confirmed Recurrent Breast Cancer
Abramson Cancer Center at Penn Medicine 600
Not applicableActive Not RecruitingNCT02321228
What this trial is testing

Early Salpingectomy (Tubectomy) With Delayed Oophorectomy in BRCA1/2 Gene Mutation Carriers

Who this might be right for
BRCA1 Gene MutationBRCA2 Gene MutationOvarian Cancer
University Medical Center Nijmegen 510
Testing effectiveness (Phase 2)Active Not RecruitingNCT03344965
What this trial is testing

Olaparib In Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerInvasive Breast CancerSomatic Mutation Breast Cancer (BRCA1)+7 more
Beth Israel Deaconess Medical Center 114
Not applicableStudy completedNCT00419510
What this trial is testing

Genetic Counseling in African American Women

Who this might be right for
Breast CancerOvarian Cancer
University of Pennsylvania 204
Early research (Phase 1)Study completedNCT01286987
What this trial is testing

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Who this might be right for
Advanced or Recurrent Solid TumorsBreast NeoplasmsOvarian Cancer, Epithelial+4 more
Pfizer 113
Testing effectiveness (Phase 2)Looking for participantsNCT04038502
What this trial is testing

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

Who this might be right for
Metastatic Castrate Resistant Prostate CancerBARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2RAD51B, RAD51C, RAD51D, or RAD54L Mutations
VA Office of Research and Development 100
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07765836
What this trial is testing

Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC

Who this might be right for
Pancreatic Cancer Metastatic
Massachusetts General Hospital 40
Not applicableStudy completedNCT05264532
What this trial is testing

Usefulness of Video-Based Intervention in Helping Participants Encourage Their Families to Get Tested for BRCA Gene Mutations

Who this might be right for
BRCA1 Gene MutationBRCA2 Gene Mutation
Ohio State University Comprehensive Cancer Center 58
Testing effectiveness (Phase 2)Study completedNCT02953457
What this trial is testing

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

Who this might be right for
BRCA1 Gene MutationBRCA2 Gene MutationOvarian Serous Adenocarcinoma+3 more
Roswell Park Cancer Institute 40
Large-scale testing (Phase 3)Study completedNCT01945775
What this trial is testing

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)

Who this might be right for
Breast NeoplasmsBRCA 1 Gene MutationBRCA 2 Gene Mutation
Pfizer 431
Early research (Phase 1)Ended earlyNCT04182516
What this trial is testing

Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors

Who this might be right for
Advanced/Metastatic Solid Tumors
Nerviano Medical Sciences 52
Not applicableStudy completedNCT01948609
What this trial is testing

Prospective Research of Outcomes After Salpingo-oophorectomy

Who this might be right for
BRCA1 Gene MutationBRCA2 Gene Mutation
University of California, San Francisco 100
Not applicableStudy completedNCT02197000
What this trial is testing

A Nutritional Intervention to Decrease Breast Density Among Female BRCA (BReast CAncer Susceptibility Gene) Carriers

Who this might be right for
BRCA1 Gene MutationBRCA2 Gene Mutation
Rabin Medical Center 23
Testing effectiveness (Phase 2)Active Not RecruitingNCT04584255
What this trial is testing

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Who this might be right for
Stage I Breast CancerStage II Breast CancerStage III Breast Cancer+5 more
Dana-Farber Cancer Institute 62
Testing effectiveness (Phase 2)Active Not RecruitingNCT02286687
What this trial is testing

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

Who this might be right for
Advanced Malignant NeoplasmATM Gene MutationBRCA1 Gene Mutation+5 more
M.D. Anderson Cancer Center 150
Next Page